Show simple item record

dc.contributor.authorLauinger, Ina L.
dc.contributor.authorVivas, Livia
dc.contributor.authorPerozzo, Remo
dc.contributor.authorStairiker, Christopher
dc.contributor.authorTarun, Alice
dc.contributor.authorZloh, Mire
dc.contributor.authorZhang, Xujie
dc.contributor.authorXu, Hua
dc.contributor.authorTonge, Peter J.
dc.contributor.authorFranzblau, Scott G.
dc.contributor.authorPham, Duc-Hung
dc.contributor.authorEsguerra, Camila V.
dc.contributor.authorCrawford, Alexander D.
dc.contributor.authorMaes, Louis
dc.contributor.authorTasdemir, Deniz
dc.date.accessioned2018-09-20T16:14:05Z
dc.date.available2018-09-20T16:14:05Z
dc.date.issued2013-06-28
dc.identifier.citationLauinger, Ina L. Vivas, Livia; Perozzo, Remo; Stairiker, Christopher; Tarun, Alice; Zloh, Mire; Zhang, Xujie; Xu, Hua; Tonge, Peter J.; Franzblau, Scott G.; Pham, Duc-Hung; Esguerra, Camila V.; Crawford, Alexander D.; Maes, Louis; Tasdemir, Deniz (2013). Potential of lichen secondary metabolites againstplasmodiumliver stage parasites with fas-ii as the potential target. Journal of Natural Products 76 (6), 1064-1070
dc.identifier.issn0163-3864,1520-6025
dc.identifier.urihttp://hdl.handle.net/10379/12389
dc.description.abstractChemicals targeting the liver stage (LS) of the malaria parasite are useful for causal prophylaxis of malaria. In this study, four lichen metabolites, evernic acid (1); vulpic acid (2), psoromic acid (3), and, (+)-usnic acid (4), were evaluated against LS parasites of Plasmodium berghei. Inhibition Of P. falciparum blood Stage (BS) parasites was also assessed to determine stage specificity. Compound 4 displayed the highest LS activity and stage specificity (LS IC50 value 2.3 mu M, BS IC50 value 47.3 mu M). The compounds 1 - 3 inhibited one Or more enzymes (Pf FabI, PfFabG, and pfFabZ), from the Plasmodial fatty acid biosynthesis (FAS-II) pathway, a potential drug. target for LS activity. To determine species specificity and to clarify the mechanism of reported antibacterial effects, 1-4 were also evaluated against FabI homologues and Whole cells of various pathogens -(S. aureus, E. coli M. tuberculosis). Molecular modeling studies suggest that lichen acids act indirectly via binding to allosteric sites on the protein surface of the FAS-II enzymes. Potential. toxicity, of compounds was assessed in human hepatocyte and cancer cells (in vitro) as well as in a zebrafish model (in vivo):. This study indicates the therapeutic and prophylactic potential of lichen metabolites as antibacterial and antiplasmodial agents.,
dc.publisherAmerican Chemical Society (ACS)
dc.relation.ispartofJournal of Natural Products
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/ie/
dc.subjectfatty-acid biosynthesis
dc.subjectcarrier protein reductase
dc.subjectenoyl-acp reductase
dc.subjectusnic acid
dc.subjectin-vitro
dc.subjectantimycobacterial activity
dc.subjectstaphylococcus-aureus
dc.subjectantimalarial activity
dc.subjectdrug discovery
dc.subjectfalciparum
dc.titlePotential of lichen secondary metabolites againstplasmodiumliver stage parasites with fas-ii as the potential target
dc.typeArticle
dc.identifier.doi10.1021/np400083k
dc.local.publishedsourcehttp://europepmc.org/articles/pmc4119598?pdf=render
nui.item.downloads0


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland